A Study Of PF-06664178 In Patients With Advanced Solid Tumors

• Drug: PF-06664178
  
  Part 1 - PF-06664178 will be administered intravenously every 21 days in cohorts of 2 or more patients starting at a dose of 0.15 mg/kg. Increases in dose will continue until MTD is determined.
• Drug: PF-06664178
  
  Part 2 - patients with select tumor types (Non Small Cell Lung Cancer ovarian cancer, and breast cancer ) will be treated at the MTD selected in Part 1.

Inclusion Criteria:

• Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy or for whom no standard therapy is available
• Performance Status of 0 or 1
• Adequate bone marrow, kidney and liver function
• Part 2 includes target expressing NSCLC, ovarian or breast cancer patients

Exclusion Criteria:

• Brain metastases requiring steroids
• Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of study treatment start (6 weeks for mitomycin C or nitrosoureas)
• Active and clinically significant bacterial, fungal, or viral infection